HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

10.220

-0.350-3.31%

Volume:354.50K

Turnover:3.59M

Market Cap:5.29B

PE:-16.53

High:10.500

Open:10.500

Low:9.935

Close:10.570

52wk High:96.900

52wk Low:9.935

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:0.97

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.618

ROE:-19.61%

ROA:-9.68%

PB:3.51

PE(LYR):-16.53

PS:43.93

Loading ...

Overview Company News Filings

BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology

XuanZhuBio-B Forges Licensing and Supply Pact for Cancer Drugs with Boston Oncology

Xuanzhu Biopharm licenses breast cancer, lung cancer drugs to Boston Oncology in MENA deal

Xuanzhu Biopharmaceutical - Group to Receive Payments Exceeding $100 Mln and Royalties Under Agreement

THOMSON REUTERS

Xuanzhu Biopharmaceutical - Xuanzhubio-B Enters Licensing Agreement With Boston Oncology for Bireociclib and Dirozalkib on April 9, 2026

THOMSON REUTERS

Stock Track | XUANZHUBIO-B Soars 12.96% in Morning Session on Strong FY2025 Earnings

XUANZHUBIO-B Shares Surge Over 12% in Morning Session on Strong FY2025 Earnings

XuanZhu Bio-B Reports Annual Revenue Surge of 72.03% to 51.772 Million Yuan

Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million

XuanZhuBio-B Shares Surge Over 18% Following Publication of Bireociclib Phase III Trial Results in Top Medical Journal

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress

XUANZHUBIO-B (02575) Final Analysis of Phase III Trial for Bireociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Published in Top-Tier Journal JAMA Oncology

Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

XuanZhuBio-B Completes Patient Enrollment for Phase III Trial of Novel GERD Treatment in China

Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis

Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets

Xuanzhu Bio-B Shares Surge Over 60% Following New Drug Approval and Inclusion in Stock Connect

Innovation Value Realization Accelerates as Inclusion in Stock Connect Finalized, XuanzhuBio-B (02575) Enters Key Investment Window

Hong Kong Market Announcement Highlights | Mengniu Dairy Projects Annual Attributable Profit of Approximately RMB 1.4 to 1.6 Billion

XUANZHUBIO-B (02575) Included in Hong Kong Stock Connect List

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02575/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":10.22,"timestamp":1788158839064,"preClose":10.57,"halted":0,"volume":354500,"delay":0,"changeRate":-0.03311258278145692,"floatShares":517947790,"shares":518000000,"eps":-0.6181851462795146,"marketStatus":"Trading","change":-0.35,"latestTime":"08-31 14:49:34","open":10.5,"high":10.5,"low":9.935,"amount":3593245,"amplitude":0.053453,"askPrice":10.26,"askSize":500,"bidPrice":10.22,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.4912297458138659,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788163800000},"marketStatusCode":2,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":10.57,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.965541,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-9.68%","roe":"-19.61%","lyrEps":-0.618185,"volumeRatio":0.965541,"shares":518000000,"dividePrice":0,"high":10.5,"amplitude":0.053453,"preClose":10.57,"low":9.935,"week52Low":9.935,"pbRate":"3.51","psRate":"43.93","week52High":96.9,"institutionHeld":0,"latestPrice":10.22,"eps":-0.6181851462795146,"divideRate":0,"volume":354500,"delay":0,"ttmEps":-0.4912297458138659,"open":10.5,"prevYearClose":70.5,"prevWeekClose":10.57,"prevMonthClose":10.99,"prevQuarterClose":13.33,"fiveDayClose":10.34,"twentyDayClose":11.58,"sixtyDayClose":17.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-08-28","current":-20.804929,"percent":0.900943,"low":-70.039607,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"high":-18.714723,"avg":-41.794487,"sd":14.235444,"marketCap":5474708140},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557},{"date":"2026-08-28","current":-22.359148,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"marketCap":5474708140}],"updateTime":1788158974106},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626990782","title":"BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2626990782","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626990782?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:44","pubTimestamp":1775724248,"startTime":"0","endTime":"0","summary":"BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston OncologyApril 9  - Xuanzhu Biopharmaceutical Co Ltd 2575.HK:XUANZHUBIO-B ENTERS LICENSING AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB ON APRIL 9, 2026BOSTON ONCOLOGY GRANTED EXCLUSIVE LICENSE FOR BIREOCICLIB AND DIROZALKIB IN 21 MENA COUNTRIESGROUP TO RECEIVE PAYMENTS EXCEEDING $100 MILLION AND ROYALTIES UNDER AGREEMENTFurther company coverage: 2575.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1515","BK1593","BK1191","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158022839","title":"XuanZhuBio-B Forges Licensing and Supply Pact for Cancer Drugs with Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1158022839","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158022839?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:38","pubTimestamp":1775723905,"startTime":"0","endTime":"0","summary":"XuanZhuBio-B (02575) announced that on April 9, 2026, the Group, as the licensor, entered into a licensing and supply agreement with Boston Oncology CGT Holding Co. Limited, the licensee, concerning...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626211902","title":"Xuanzhu Biopharm licenses breast cancer, lung cancer drugs to Boston Oncology in MENA deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2626211902","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626211902?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723686,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharm signed licensing and supply agreement with Boston Oncology CGT on April 9, 2026, covering cancer drugs bireociclib and dirozalkib.Deal grants Boston Oncology exclusive rights to develop, register, commercialize both drugs across 21 Middle East and North Africa markets.Xuanzhu Biopharm expects upfront payment, regulatory and commercial milestones that may exceed USD 100 million.Agreement also includes royalties at fixed percentage of sales in licensed territory.Xuanzhu Biopharm will supply products to Boston Oncology at agreed supply prices to support commercialization in region.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news br","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4tmr89:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","02575","BK1191","BK1593","BK1600","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902213","title":"Xuanzhu Biopharmaceutical - Group to Receive Payments Exceeding $100 Mln and Royalties Under Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626902213?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:33","pubTimestamp":1775723618,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0JV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626024259","title":"Xuanzhu Biopharmaceutical - Xuanzhubio-B Enters Licensing Agreement With Boston Oncology for Bireociclib and Dirozalkib on April 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626024259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626024259?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:33","pubTimestamp":1775723618,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160268323","title":"Stock Track | XUANZHUBIO-B Soars 12.96% in Morning Session on Strong FY2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1160268323","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160268323?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:53","pubTimestamp":1775094813,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B's stock price soared 12.96% during the morning trading session, following the release of the company's annual financial results for the fiscal year ending December 31, 2025.The surge is...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121401258","title":"XUANZHUBIO-B Shares Surge Over 12% in Morning Session on Strong FY2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1121401258","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121401258?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:50","pubTimestamp":1775094646,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its shares rise more than 12% during the morning trading session. As of the time of writing, the stock was up 12.24%, trading at HK$34, with a turnover of HK$6.5058 million....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1191","02575","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114719347","title":"XuanZhu Bio-B Reports Annual Revenue Surge of 72.03% to 51.772 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1114719347","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114719347?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:06","pubTimestamp":1774865209,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 51.772 million yuan, representing a year-on-year increase of 72.03%. Gross...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315221","title":"Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315221?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:58","pubTimestamp":1774864687,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical posted a net loss of RMB 250 million, narrowing 55.9%.Operating expenses fell 56.6% to RMB 250 million.Commercial rollout accelerated with two oncology launches in 2025, while cash and cash equivalents climbed to RMB 650 million following the October IPO.For 2026, focus remains on expanding NRDL access, advancing indication expansions and pipeline development, while tightening cost management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL414TVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","00460","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187286061","title":"XuanZhuBio-B Shares Surge Over 18% Following Publication of Bireociclib Phase III Trial Results in Top Medical Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1187286061","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187286061?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490060,"startTime":"0","endTime":"0","summary":"XuanZhuBio-B (02575) rose more than 18% during morning trading. At the time of writing, the stock was up 11.85% to HK$40.58, with a turnover of HK$18.864 million. The surge follows an announcement on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000516","BK0188","BK4588","BK0236","VXUS","BK4585","BK0042","02575","BK0146","BK0181","BK0046","BK1191","BK0096","III","BK4134","BK0077","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148472362","title":"HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148472362","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148472362?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490045,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. XuanzhuBio up 9%; Xtalpi, Lepu Bio and Ascletis up 6%; Akeso up 5%; Skb Bio up 4%. ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06606","02268","02228","01672","09966","09995","02575","02137","03347","09688","03759","06978","02359","02269","02157","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198477232","title":"XUANZHUBIO-B (02575) Final Analysis of Phase III Trial for Bireociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Published in Top-Tier Journal JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1198477232","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198477232?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774351001,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that the final analysis results of the Phase III BRIGHT-2 clinical study for its self-developed novel CDK2/4/6 inhibitor, Bireociclib, have been formally published...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK4225","02575","BK1191","BK4203","HR","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069888","title":"Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069888","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069888?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:06","pubTimestamp":1774350387,"startTime":"0","endTime":"0","summary":"Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death .In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL20tgp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","00460","02575","BK1593","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170342211","title":"XuanZhuBio-B Completes Patient Enrollment for Phase III Trial of Novel GERD Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1170342211","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170342211?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:36","pubTimestamp":1774175781,"startTime":"0","endTime":"0","summary":"XuanZhuBio-B (02575) has announced the successful completion of patient enrollment for the Phase III clinical trial in China of its self-developed innovative drug, Anaprazole Sodium Enteric-coated...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4134","02575","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621714840","title":"Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714840","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621714840?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:08","pubTimestamp":1774174088,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis. Xuanzhu reported full enrollment of 500 adults in a China Phase 3 trial of its product Anaprazole Sodium enteric-coated tablets  for reflux esophagitis.The trial milestone positions the program for potential expansion beyond Anaprazole’s existing China approval for duodenal ulcer treatment.Completion of enrollment may support near-term differentiation in the domestic reflux esophagitis market by advancing a locally developed therapy through late-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL6JMbm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","02575","BK1600","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621714823","title":"Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714823","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621714823?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:08","pubTimestamp":1774174083,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets. Xuanzhu Biopharma reported completion of enrollment of 500 subjects in a China Phase III trial of anaprazole sodium enteric-coated tablets  for adult reflux esophagitis.The pivotal study is multi-center, randomized, double-blind, double-dummy, and active-controlled.The primary endpoint is endoscopic healing rate within 8 weeks of treatment.Secondary endpoints include endoscopic healing rate at week 4 and symptom changes at week 4 and week 8.No trial results were reported in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original conten","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL8162Qw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1600","00460","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166422213","title":"Xuanzhu Bio-B Shares Surge Over 60% Following New Drug Approval and Inclusion in Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1166422213","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166422213?lang=en_us&edition=fundamental","pubTime":"2026-03-19 10:20","pubTimestamp":1773886841,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1191","VXUS","02575","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145286940","title":"Innovation Value Realization Accelerates as Inclusion in Stock Connect Finalized, XuanzhuBio-B (02575) Enters Key Investment Window","url":"https://stock-news.laohu8.com/highlight/detail?id=1145286940","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145286940?lang=en_us&edition=fundamental","pubTime":"2026-03-17 08:33","pubTimestamp":1773707595,"startTime":"0","endTime":"0","summary":"Recent policy developments have been consistently favorable for innovative drugs. This year's Government Work Report presented at the National People's Congress listed biopharmaceuticals alongside...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112141928","title":"Hong Kong Market Announcement Highlights | Mengniu Dairy Projects Annual Attributable Profit of Approximately RMB 1.4 to 1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1112141928","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112141928?lang=en_us&edition=fundamental","pubTime":"2026-03-09 09:17","pubTimestamp":1773019041,"startTime":"0","endTime":"0","summary":"Significant Corporate Developments: Hengrui Pharmaceuticals (01276) announced that its adebelisib injection has received a drug clinical trial approval notice. Anjoy Foods (02648) plans to inject an...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0173614495.USD","LU0315179316.USD","LU2125910500.SGD","LU0594300419.USD","BK1521","LU0328353924.USD","LU0029875118.USD","IE00B29SXG58.USD","LU1051768304.USD","VT","LU0737861699.HKD","BK4585","IE0008369823.USD","VXUS","BK4588","BK1589","LU0128522157.USD","LU1115378108.SGD","HK0000320223.HKD","LU1439103000.SGD","BK1191","IE00B031J352.USD","02319","LU0543330483.HKD","02575","LU0228367735.SGD","BK1597","LU0348788117.USD","LU0651946864.USD","LU1224709979.USD","IE0008368742.USD","HK0000306685.HKD","LU0326950275.SGD","LU0106959298.USD","LU1102505929.USD","LU0650527681.SGD","LU0048580855.USD","LU2045819591.USD","LU1769817179.HKD","LU0359202008.SGD","LU0370786039.SGD","LU0672654166.SGD","IE0009570106.USD","IE00B031HY20.USD","LU0072462343.USD","BK1553","02652","IE0031814852.USD","IE00B97KM107.HKD","LU1048588211.SGD","HK0000306701.USD","LU0251143458.SGD","LU1102505762.USD","LU0211977185.USD","LU0259732245.USD","LU0163747925.USD","LU0320764755.SGD","IE00B067MR52.USD","LU0823426480.USD","LU0307460666.USD","BK1237","LU0228659784.USD","LU0359201612.USD","HK0000320264.USD","IE00B0169L03.USD","LU1023057109.AUD","SG9999002828.SGD","LU0287142896.SGD","LU0359201885.HKD","LU1769817096.USD","LU0823426308.USD","IE0032834883.USD","LU0640798160.USD","LU0471298777.SGD","LU1515016050.SGD","LU0385154629.USD","SG9999011746.SGD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110675696","title":"XUANZHUBIO-B (02575) Included in Hong Kong Stock Connect List","url":"https://stock-news.laohu8.com/highlight/detail?id=1110675696","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110675696?lang=en_us&edition=fundamental","pubTime":"2026-03-08 18:22","pubTimestamp":1772965333,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that, based on separate notices issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange on March 6, 2026, the company has been added to the list of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","VXUS","BK4585","02575","VT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":87,"code":"91000000","status":"200"}]}}